Branchburg, New Jersey (PRWEB) June 25, 2013
ZEUS Scientific is pleased to announce the formation of a corporate board and the appointment of John Moore, W. Barry McDonald and Tim Rothwell to this board. The mandate of this board is to counsel ZEUS Executive Management on strategic business matters and corporate growth opportunities. The appointed board members each carry decades of executive leadership positions across multiple industries, including in vitro diagnostics, pharmaceuticals, finance and investment banking. Amongst their many achievements Mr. Moore has been an officer of a number of investment banking firms in New York City, Mr. McDonald has served as President and CEO of Mast/Hitachi, and Mr. Rothwell has served as President and CEO of Sanofi-Aventis U.S. The board members also have diverse formal educational backgrounds including studies in the biological sciences, business and law.
In addition to the formation of this corporate board, ZEUS Scientific has recently updated its corporate structure. Co-owner Scott Tourville remains as Chief Executive Officer of ZEUS Scientific and co-owner John Tourville has been appointed as Chief Operating Officer.
Further details of the ZEUS Executive Team and Board of Advisors can be found on the ZEUS Scientific corporate website http://www.zeusscientific.com/about-us/leadership/.
About ZEUS Scientific
ZEUS Scientific has over 35 years of experience in developing, manufacturing and marketing in vitro diagnostic laboratory tests. No other company offers the breadth and depth of products across both autoimmune disease and infectious serology testing, across three methodologies: IFA, ELISA and multiplex (AtheNA Multi-Lyte®). ZEUS Scientific is based in Branchburg, New Jersey and markets test systems around the world through an extensive distribution network. ZEUS Scientific complies with the international standard ISO 13485 (2003), Health Canada Medical Device Regulations (SOR/98-282, May 7 1998), the FDA Quality System Regulations (FDA Quality System Regulation, 1996: 21 CFR § 820), and the IVD 98/79/EEC.
For more information visit: http://www.zeusscientific.com or call +1 (908) 526 3744.